Frontline Tecentriq plus chemotherapy improves lung cancer survival
The phase 3 trial evaluating the addition of first-line atezolizumab to chemotherapy met its coprimary endpoints of OS and PFS among patients with previously untreated advanced nonsquamous non-small cell lung cancer.
Atezolizumab (Tecentriq, Genentech/Roche) — a monoclonal PD-L1 antibody — is indicated for the treatment of patients with previously treated metastatic NSCLC, as well as patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin chemotherapy, or who have had disease progression during or following platinum-containing therapy.
In the multicenter, open-label IMpower130 trial, researchers randomly assigned 724 patients with chemotherapy-naive stage IV nonsquamous NSCLC to atezolizumab plus carboplatin and nab-paclitaxel or chemotherapy alone.
According to interim results released by the manufacturer, IMpower130 met its coprimary endpoints of improved PFS and OS among patients treated with atezolizumab plus chemotherapy.
“The results of the IMpower130 study add to the growing evidence showing the clinical benefit of Tecentriq-based combinations in the treatment of advanced nonsquamous NSCLC,” Sandra Horning, MD, chief medical officer and head of global product development at Roche, said in a press release. “We will share these results with global health authorities with the goal of bringing this potential treatment option to people with this disease.”
The safety for the atezolizumab and chemotherapy combination appeared consistent with the known safety profile of the individual agents. Researchers observed no new safety signals.